Naturalistic Study of Microdosing With Psilocybin
NCT05160220, Not applicable, Completed, National Council of Scientific and Technical Research, Argentina
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Naturalistic Study of Microdosing With Psilocybin | ClinicalTrials.gov |
| NCT number | NCT05160220 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 34 participants, actual | ClinicalTrials.gov |
| Lead sponsor | National Council of Scientific and Technical Research, Argentina | ClinicalTrials.gov |
| Conditions | Cognitive Change, Creativity, Mood Change, Sleep | ClinicalTrials.gov |
| Interventions | Psilocybin, Placebo | ClinicalTrials.gov |
| First posted | 2021-12-16 | ClinicalTrials.gov |
| Last updated | 2021-12-16 | ClinicalTrials.gov |
Registered outcomes 15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Resting state oscillations measured with EEG | 1 week | Our goal is to study changes in spectral content before and during the acute effects with the purpose of comparing changes with those observed under higher doses of psilocybin. | ClinicalTrials.gov |
| Primary | Attention | 1 week | Measured performance in the attentional blink paradigm | ClinicalTrials.gov |
| Primary | Inhibitory control | 1 week | Measured using the go/no go experimental paradigm | ClinicalTrials.gov |
| Primary | Conscious access | 1 week | Measured using the backward masking paradigm | ClinicalTrials.gov |
| Primary | Visual perception | 1 week | Measured using the binocular rivalry paradigm | ClinicalTrials.gov |
| Primary | Physical activity | 1 week | Measured using wrist actigraphy using a smartwach | ClinicalTrials.gov |
| Primary | Divergent thinking | 1 week | Measured using the Alternative Uses Task (AUT) | ClinicalTrials.gov |
| Primary | Attention | 1 week | Measured using the hiearchical mismatch negativity paradigm combined with EEG | ClinicalTrials.gov |
| Primary | Cognitive flexibility | 1 week | Measured using the stroop task | ClinicalTrials.gov |
| Primary | Convergent thinking | 1 week | Measured using the Remote Associations Task (RAT) | ClinicalTrials.gov |
| Primary | Convergent thinking | 1 week | Measured using the Wallach-Kogan test (WK) | ClinicalTrials.gov |
| Secondary | Effect positive/negative affect and well-being | 1 week | Measured using the Positive and Negative Affect Schedule (PANAS) | ClinicalTrials.gov |
| Secondary | Effects on anxiety | 1 week | Measured using State Trait Anxiety Inventory (STAI) | ClinicalTrials.gov |
| Secondary | Effects on personality | 1 week | Measured using the Big Five inventory (BFI) | ClinicalTrials.gov |
| Secondary | Concentration of psilocybin in the dried material | 1 week | To be measured using high performance liquid chromatography | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Alternative Uses Task | Primary outcome | ConductCognition |
| Attentional Blink Task | Primary outcome | ConductCognition |
| Backward Masking Task | Primary outcome | ConductCognition |
| Go/No-Go Task | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)